Tags

Type your tag names separated by a space and hit enter

Comparing bimatoprost and travoprost in black Americans.
Curr Med Res Opin. 2006 Nov; 22(11):2175-80.CM

Abstract

OBJECTIVE

To compare the intraocular pressure-lowering efficacy and safety of topical bimatoprost 0.03% with that of travoprost 0.004% for the treatment of black patients with open-angle glaucoma (OAG) and ocular hypertension (OHT).

RESEARCH DESIGN AND METHODS

Multicenter, prospective, randomized, investigator-masked trial of 94 black patients previously diagnosed with OAG or OHT. All patients completed washout of ocular hypotensive medications before study participation. Patients were assigned to either once-daily bimatoprost 0.03% or once-daily travoprost 0.004% for 3 months.

MAIN OUTCOME MEASURES

The primary outcome measures were mean intraocular pressure (IOP), mean change from baseline IOP, and percentage of patients who reached a target IOP reduction. Secondary measures included ophthalmologic examination and adverse events.

RESULTS

Both bimatoprost and travoprost significantly lowered IOP at all study visits (p < 0.001). Bimatoprost provided mean IOP reductions from baseline that ranged from 6.8 mmHg to 7.8 mmHg (27% to 31%). Travoprost provided mean IOP reductions from baseline that ranged from 6.2 mmHg to 6.9 mmHg (25% to 28%). By month 3, 85% of participants in the bimatoprost group had a mean IOP reduction of at least 20%, compared with 68% of those in the travoprost group. Furthermore, 31.9% of those in the bimatoprost group had a mean IOP reduction of more than 40% at month 3 compared with 20.9% of those in the travoprost group. There were no significant differences in biomicroscopy, ophthalmoscopy, or visual acuity. Ocular redness was the most commonly reported adverse event in both treatment groups. No serious adverse events were reported.

CONCLUSIONS

Bimatoprost and travoprost each effectively lowered IOP in this population of black patients. More patients achieved clinically relevant IOP reductions with bimatoprost.

Authors+Show Affiliations

Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA. noeckerrj@UPMC.EDUNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17076978

Citation

Noecker, Robert J., et al. "Comparing Bimatoprost and Travoprost in Black Americans." Current Medical Research and Opinion, vol. 22, no. 11, 2006, pp. 2175-80.
Noecker RJ, Earl ML, Mundorf TK, et al. Comparing bimatoprost and travoprost in black Americans. Curr Med Res Opin. 2006;22(11):2175-80.
Noecker, R. J., Earl, M. L., Mundorf, T. K., Silverstein, S. M., & Phillips, M. P. (2006). Comparing bimatoprost and travoprost in black Americans. Current Medical Research and Opinion, 22(11), 2175-80.
Noecker RJ, et al. Comparing Bimatoprost and Travoprost in Black Americans. Curr Med Res Opin. 2006;22(11):2175-80. PubMed PMID: 17076978.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparing bimatoprost and travoprost in black Americans. AU - Noecker,Robert J, AU - Earl,Melissa L, AU - Mundorf,Thomas K, AU - Silverstein,Steven M, AU - Phillips,Michael P, PY - 2006/11/2/pubmed PY - 2006/12/9/medline PY - 2006/11/2/entrez SP - 2175 EP - 80 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 22 IS - 11 N2 - OBJECTIVE: To compare the intraocular pressure-lowering efficacy and safety of topical bimatoprost 0.03% with that of travoprost 0.004% for the treatment of black patients with open-angle glaucoma (OAG) and ocular hypertension (OHT). RESEARCH DESIGN AND METHODS: Multicenter, prospective, randomized, investigator-masked trial of 94 black patients previously diagnosed with OAG or OHT. All patients completed washout of ocular hypotensive medications before study participation. Patients were assigned to either once-daily bimatoprost 0.03% or once-daily travoprost 0.004% for 3 months. MAIN OUTCOME MEASURES: The primary outcome measures were mean intraocular pressure (IOP), mean change from baseline IOP, and percentage of patients who reached a target IOP reduction. Secondary measures included ophthalmologic examination and adverse events. RESULTS: Both bimatoprost and travoprost significantly lowered IOP at all study visits (p < 0.001). Bimatoprost provided mean IOP reductions from baseline that ranged from 6.8 mmHg to 7.8 mmHg (27% to 31%). Travoprost provided mean IOP reductions from baseline that ranged from 6.2 mmHg to 6.9 mmHg (25% to 28%). By month 3, 85% of participants in the bimatoprost group had a mean IOP reduction of at least 20%, compared with 68% of those in the travoprost group. Furthermore, 31.9% of those in the bimatoprost group had a mean IOP reduction of more than 40% at month 3 compared with 20.9% of those in the travoprost group. There were no significant differences in biomicroscopy, ophthalmoscopy, or visual acuity. Ocular redness was the most commonly reported adverse event in both treatment groups. No serious adverse events were reported. CONCLUSIONS: Bimatoprost and travoprost each effectively lowered IOP in this population of black patients. More patients achieved clinically relevant IOP reductions with bimatoprost. SN - 1473-4877 UR - https://www.unboundmedicine.com/medline/citation/17076978/Comparing_bimatoprost_and_travoprost_in_black_Americans_ L2 - http://www.tandfonline.com/doi/full/10.1185/030079906X148418 DB - PRIME DP - Unbound Medicine ER -